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BRD9 binds cell type-speciﬁc chromatin
regions regulating leukemic cell survival via
STAT5 inhibition
Nunzio Del Gaudio1, Antonella Di Costanzo1, Ning Qing Liu2, Lidio Conte1, Antimo Migliaccio 1, Michiel Vermeulen3,
Joost H. A. Martens1,3, Hendrik G. Stunnenberg 3, Angela Nebbioso1 and Lucia Altucci 1
Abstract
Leukemia is characterized by genetic and epigenetic mutations resulting in selection of cancer cells, which are unable
to differentiate. Although genetic alterations are difﬁcult to target, the epigenome is intrinsically dynamic and readily
offers new therapeutic strategies. Thus, identifying cancer-speciﬁc context-dependent targets and unraveling their
biological function may open up new therapeutic perspectives. Here we identify bromodomain-containing protein 9
(BRD9) as a critical target required in acute myeloid leukemia (AML). We show that BRD9 is overexpressed in AML cells
including ex vivo primary blasts compared with CD34+ cells. By targeting BRD9 expression in AML, we observed an
alteration in proliferation and survival, ultimately resulting in the induction of apoptosis. Intriguingly, genome-wide
proﬁling revealed that BRD9 binds enhancer regions in a cell type-speciﬁc manner, regulating cell type-related
processes. We unveil a novel BRD9-sustained STAT5 pathway activation via regulation of SOCS3 expression levels. Our
ﬁndings identify a previously undescribed BRD9-STAT5 axis as critical for leukemia maintenance, suggesting BRD9 as a
potential therapeutic target.
Introduction
Leukemia is a hematological malignancy characterized
by neoplastic clones that are unable to differentiate1.
Although recurring protein-coding mutations and chro-
mosomal aberrations are essential to leukemic patho-
genesis, epigenetic mutations critically contribute to its
development and/or maintenance2. DNA methylation and
histone posttranslational modiﬁcation machinery together
with proteins specialized for the interpretation of histone
modiﬁcation (readers) all contribute to leukemogenesis.
Readers are deﬁned as chromatin regulators possessing
speciﬁc domains that recognize and bind covalent mod-
iﬁcations of nucleosomes3. Bromodomain-containing
proteins (BRDs) speciﬁcally bind acetylated lysines via
an evolutionarily conserved protein interaction module.
BRDs are principally involved in gene transcription reg-
ulation, cell cycle control, cell growth, DNA damage
response, inﬂammation, and development4,5.
Several BRDs, functioning as either oncogenes or tumor
suppressors (TSs), have been implicated in cancer devel-
opment and maintenance, making them attractive phar-
macological targets for future anticancer strategies6. For
example, overexpression of the histone readers ATAD2
and TRIM24 was associated with poor overall survival in
breast cancer7, whereas BRDT protein was frequently
found overexpressed in non-small cell lung cancer and
other low survival cancers8. In addition, two different
short hairpin RNA (shRNA) screening-based studies
identiﬁed BRD4 and SMARCA4 as targets for acute
myeloid leukemia (AML) development and maintenance,
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sustaining the transcription of MYC and HOXA9/MEIS,
respectively, and leading to abnormal differentiation,
proliferation, and survival9,10.
Besides SMARCA4, other SWI/SNF subunit proteins
with a BRD module were shown to be involved in cancer,
including BRD711. Several studies described BRD7 as a
TS, whose expression is downregulated in multiple cancer
types including nasopharyngeal, endometrial, and hepa-
tocellular carcinomas12, as well as ovarian and colorectal
cancers13. BRD7 is also reported to interact with BRCA-1
and p53, contributing to suppression of breast cancer cell
survival mechanisms14. Although the role of BRD7 in
cancer has been extensively studied, the biological func-
tion and involvement in human malignancies of its close
homolog BRD9 has not yet been elucidated. Here we
identify BRD9 as critically required in AML. We reveal
that BRD9 is overexpressed in AML cells, including
ex vivo primary blasts, compared with CD34+. In support
of the leukemogenic role of BRD9, shBRD9-expressing
AML cells displayed a strong impairment of proliferation
and survival, accompanied by induction of apoptosis.
Interestingly, BRD9 preferably binds enhancer regions in
a cell type-speciﬁc manner, regulating cell type-related
processes. Our study of BRD9 epigenome regulation in
AML supports the hypothesis that the effects of
BRD9 suppression are due to its role in sustaining STAT5
pathway activation via SOCS3 expression level regulation.
Our data provide new insights into the function of BRD9
in cancer and suggest BRD9 as a novel potential ther-
apeutic target in leukemia.
Results
BRD9 is overexpressed in cancer
To investigate the involvement of BRD9 in human
leukemia, we ﬁrst analyzed BRD9 expression levels in 200
clinically annotated AML samples (The Cancer Genome
Atlas (TGCA); Ley et al.15), 19 non-transformed human
bone marrow progenitor samples (Hematopoietic Stem
Cells (HSCs), MultiPotent Progenitors (MPPs), Common
Myeloid Progenitors (CMPs), Common Lymphoid Pro-
genitors (CLPs), Granulocyte-Monocyte Progenitors
(GMPs), Megakaryocyte-Erythrocyte Progenitors
(MEPs)), and 16 differentiated human hematopoietic cell
samples (monocytes and macrophages) (Blueprint data
set). The results were shown as dot plot representing
BRD9 expression value in samples belonging to the spe-
ciﬁc cell-type subgroup. AML samples exhibited increased
BRD9 expression compared with progenitors and differ-
entiated cells, whereas no difference was observed
between AML samples belonging to different cell sub-
group based on World Health Organization leukemic
classiﬁcation (Fig. 1a, Supplementary Fig. 1a).
To corroborate BRD9 overexpression in AML, we
examined BRD9 expression levels in ﬁve ex vivo primary
human AML blasts compared with CD34+. BRD9
expression was signiﬁcantly higher in all leukemic blasts
than in CD34+ cells (Fig. 1b).
To further conﬁrm this ﬁnding, we evaluated BRD9
protein levels in a panel of human hematological and solid
cancer cell lines compared with CD34+ and non-
transformed cells (primary endometrial cells), respec-
tively. BRD9 protein levels were dramatically increased in
all cancer/tumorigenic cells analyzed. In contrast, very
low levels of BRD9 protein were detected in normal and
CD34+ progenitors (Fig. 1c, Supplementary Fig. 1b, c).
Taken together, these data indicate that BRD9 is over-
expressed in both leukemia and solid cancer cells.
AML cells are sensitive to BRD9 depletion
To investigate the potential involvement of BRD9 in
leukemia, we assayed the biological effects of shRNA-
mediated BRD9 knockdown (KD) on leukemic cell
growth. U937, K562 HL-60, KASUMI, and NB4 cells were
transduced with a lentivirus expressing shBRD9#1,
shBRD9#2, or non-targeting shRNA (shSCR) (Supple-
mentary Fig. 1d, e, f, g and h). After puromycin selection,
proliferation of BRD9 KD cells was signiﬁcantly reduced
compared to scrambled control (Fig. 2a, b, Supplementary
Fig. 2a, d). In addition, shBRD9-expressing cells were
arrested in G0/G1 phase of cell cycle and showed a
reduction in S phase compared to shSCR-transduced cells
(Fig. 2c, d). Similarly, the colony-forming capability of
U937 cells was also signiﬁcantly reduced following BRD9
depletion compared with control (Fig. 2e). In agreement
with the phenotypic results, shBRD9-expressing U937
cells revealed overexpression of p21 and downregulation
of cyclin E compared with shSCR (Fig. 2f).
Taken together, these ﬁndings indicate that BRD9 is
required for clonogenicity and proliferation of myeloid
leukemic cell lines, suggesting a possible induction of
shBRD9-mediated cell death.
BRD9 depletion induces apoptosis of cell lines and ex vivo
primary AML blasts
To explore BRD9 KD-induced cell death, the fraction of
propidium iodide (PI)-positive cells was measured.
shBRD9-expressing U937, K562, HL-60, KASUMI, and
NB4 cells displayed increased cell death percentages
compared with shSCR (Fig. 3a and Supplementary Fig. 2b,
c, e and f). We also investigated the sensitivity of ex vivo
myeloid leukemic blasts to BRD9 KD. Two ex vivo pri-
mary AML samples were collected and transduced with a
lentivirus expressing shBRD9 or shSCR. PI analysis was
performed 48 h after transduction. shBRD9-expressing
blasts showed a higher percentage of PI-positive cells than
shSCR. (Fig. 3c). Next, to address apoptosis onset as a
mechanism of observed cell death induction, protein
levels of key apoptotic genes were analyzed. U937 cells
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expressing shBRD9 showed a strong induction of caspase8
via p43/41 kDa and p18 kDa fragments, and Poly (ADP-
ribose) polymerase (PARP) via p27 kDa fragment. In
contrast, neither pro-caspase8 nor PARP cleavage were
observed in shSCR-transduced cells (Fig. 3d). In addition,
we investigate the impact of caspase inhibition on BRD9
KD cells. By PI analysis of shBRD9-tranduced cells treated
with Caspase8 and Caspase9 inhibitors, respectively, we
observed that Caspase8 inhibition was able to rescue the
shBRD9-induced cell death. Conversely, inhibition of
Caspase9 failed to rescue the phenotype. Results con-
ﬁrmed that the BRD9 KD-induced apoptosis is Caspase8
dependent (Fig. 3e). Apoptosis onset following BRD9
depletion was also conﬁrmed by Annexin-V staining assay
in both U937 and KASUMI cells (Fig. 3b, Supplementary
Fig. 2g, 3a, b).
Taken together, these ﬁndings indicate that BRD9
depletion induces apoptosis via Caspase8 activation in
both in vitro and ex vivo primary AML cells.
BRD9 is part of the SWI/SNF complex and targets putative
enhancer regions in a cell type-speciﬁc manner
To corroborate and strengthen the needed involvement
of BRD9 in AML, we addressed its molecular role in
cancer by mass spectrometry (MS)-based quantitative
interaction proteomics. We generated a transgenic HeLa
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Fig. 1 BRD9 is overexpressed in cancer. a Dot plot bioinformatics analysis showing BRD9 expression in publicly available RNA-seq data from 200
primary AML samples, 19 samples of human hematopoietic progenitors, and 16 samples of differentiated human monocyte and macrophage cells.
β-Actin was used as housekeeping gene (P < 0.01 Welch’s t-test). b RT-qPCR analysis of BRD9 expression in primary AML samples (pt) compared with
CD34+ cells; error bars indicate SD of three biological replicates (*P < 0.05, **P ≤ 0.01). c WB analysis of BRD9 in the indicated leukemic cell lines
compared with the CD34+. Actin was used as loading control. Error bars indicate SD of three biological replicates (*P < 0.05, **P ≤ 0.01)
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stable cell line overexpressing N-terminal green ﬂuor-
escent protein (GFP)-tagged BRD9 protein, downstream a
doxycycline-inducible promoter (Supplementary Fig. 3c).
After 24 h of doxycycline induction, GFP pulldown of
nuclear HeLa extracts was performed and precipitated
proteins were analyzed by liquid chromatography (LC)-
MS/MS. The results conﬁrmed the interaction of BRD9
with proteins belonging to the SWI/SNF complex—
SMARCA4, SS18, SMARCD1, and the recently identiﬁed
SWI/SNF interactors GLTSCR1 and GLTSCR1L16 clas-
sifying BRD9 as a core member of the complex (Fig. 4a).
In addition, we validated LC-MS/MS data by GFP pull-
down assay following western blotting (WB) analysis of
U937 cells expressing GFP-BRD9. Results conﬁrmed the
interaction of BRD9 with SMARCA4 (Supplementary Fig.
3d). Given that reader subunits belonging to SWI/SNF are
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expected to mediate correctly positioning of the complex
on certain genomic regulatory regions such as enhan-
cers17, we reasoned that BRD9 may also show a cell type-
speciﬁc genomic binding pattern. Thus, to identify
leukemic-speciﬁc BRD9-binding sites, we determined
genome-wide BRD9 binding using chromatin
immunoprecipitation-sequencing (ChIP-seq) in the U937
cell line and the non-hematopoietic HeLa cell line. The
majority of BRD9-binding sites were cell type speciﬁc:
U937 speciﬁc (Cluster C2, n= 2656) or HeLa speciﬁc
(Cluster C1, n= 3158), respectively, whereas a smaller
fraction of binding sites were detected in both cell lines
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(Cluster C3, n= 1272) (Fig. 4b). The cell type-speciﬁc
BRD9-binding cluster C1 in HeLa and, to a lesser extent,
C2 in U937 preferably located at putative enhancers
(>1 kb of transcription start sites [TSS]), whereas the
common binding cluster C3 showed a clear enrichment
within promoters (≤1 kb of TSS) (Fig. 4c). We further
validate ChIP-seq results by an independent ChIP-
quantitative PCR (qPCR) experiment analyzing speciﬁc
BRD9 targets (Supplementary Fig. 5d).
To reveal the potential function of BRD9-binding sites,
we performed Gene Ontology (GO) analysis on the three
clusters. GO terms associated with general cellular pro-
cesses such as transcription and translation regulation
were enriched in the common C3-binding cluster. In
contrast, we found that C1 biological processes were
associated with extracellular matrix organization and C2
GO terms were strongly linked to immune response,
which are related to epithelial and hematopoietic cells,
respectively. These data suggest that BRD9 binding at
putative enhancers regulates cell type-speciﬁc processes,
whereas at promoters it regulates common cellular pro-
cesses (Fig. 4d).
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Taken together, these ﬁndings highlight that BRD9
belongs to the SWI/SNF complex and binds certain
enhancer elements in a cell type-speciﬁc manner.
BRD9-binding sites are mainly associated with active
chromatin regions
We next examined the chromatin environment at
BRD9-binding regions. Using an integrative data analysis
of BRD9, active histone markers (H3K4me3, recently
shown to occur also at active enhancer level18 and
H3K9K14ac), and POLR2A occupancy, we found that
BRD9 co-occurs at active chromatin sites in both U937
and HeLa cells (Fig. 5a). Furthermore, we observed
transcription levels of genes associated with BRD9-
binding sites in shBRD9-transduced U937 cells. BRD9
KD resulted in dominant gene silencing in both the U937-
speciﬁc C2 cluster (4% upregulation compared with 17%
downregulation) and the universal C3 cluster (5% upre-
gulation compared with 15% downregulation) (Fig. 5b,
Supplementary Fig. 4a, b). However, a small percentage of
in cis BRD9-regulated genes was also found actively
transcribed, including sets of genes positively regulating
the apoptotic pathway (Fig. 5b, Supplementary Fig. 4a, b).
Taken together, these data highlight that BRD9 is
mainly associated with active chromatin regions, func-
tioning primarily as a transcriptional activator.
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BRD9 depletion affects key proliferation and immune
response pathways in AMLs
To identify BRD9-associated pathways, we performed
RNA sequencing (RNA-seq) on scramble- and shBRD9-
transduced U937 cells. A total of 2113 genes were
deregulated with ≥2-fold difference in expression, 412 of
which were upregulated and 1701 downregulated in
shBRD9 compared with shSCR-transduced cells. Using
gene-set enrichment analysis (GSEA) we identiﬁed the top
differential expressed gene sets up- and downregulated in
shBRD9- compared with shSCR-transduced cells. shBRD9
caused the downregulation of gene sets related to pro-
liferation (such as E2F and MYC targets) and immune
response (such as INFα and γ-targets). In contrast, the
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Fig. 6 BRD9 depletion affects STAT5 pathway activation. a RT-qPCR of indicated genes in shBRD9-transduced U937 cells. Error bars indicate SD of
three biological replicates (*P < 0.05, **P ≤ 0.01). b WB analysis of indicated proteins upon BRD9 depletion in U937 cells after 3 days upon puromycin
selection. Immunoblottings were performed sequentially on the same membrane. Error bars indicate SD of three biological replicates (*P < 0.05,
**P ≤ 0.01). c GSEA showing STAT5 hallmark gene set (P < 0.05) associated with shSCR- and shBRD9-transduced U937 cells. d RT-qPCR showing
relative expression levels of indicated genes. Experiment was performed 48 h following shBRD9 transduction of ex vivo leukemic cells (Pt 1). Error bars
indicate SD of two biological replicates (*P < 0.05, **P ≤ 0.01). e WB analysis of indicated proteins performed 48 h following BRD9 overexpression in
U937 cells. Immunoblottings were performed sequentially on the same membrane. Error bars indicate SD of three biological replicates (*P < 0.05,
**P ≤ 0.01)
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gene sets upregulated in shBRD9 cells involved apoptotic
pathways (such as p53 and tumor necrosis factor-α tar-
gets) (Fig. 5c and Supplementary Fig. 4a and c). We
validated RNA-seq results of the key deregulated genes
using reverse transcriptase-qPCR (Fig. 6a and Supple-
mentary Fig. 4b).
Altogether, these results show that BRD9 KD affects key
proliferative pathways in AML.
BRD9 promotes AML cell survival primarily via STAT5
activation
Among the in cis BRD9-target genes deregulated fol-
lowing BRD9 KD, SOCS3 was identiﬁed as one of the top
upregulated (fold change > 4.5). As a consequence, we
hypothesized that SOCS3 might be a solid candidate for
mediating the shBRD9-induced phenotype. SOCS3
negatively regulates Janus kinase family members, which
inhibits the activation of STAT proteins, including
STAT5. Activation of STAT5 has been implicated in the
stimulation of AML proliferation and survival, as well as
in inﬂammation19–21. We validated SOCS3 upregulation
upon BRD9 depletion at protein (Fig. 6b) and mRNA level
(Supplementary Fig. 4b); we also conﬁrmed that BRD9
localizes at SOCS3 regulative regions (Supplementary Fig.
5c and d). We corroborated the impairment of STAT5
activation by detecting low levels of phosphorylated
STAT5 (pSTAT5) (Fig. 6b). Reduced pSTAT5 levels
resulted in the downregulation of key proliferative (PCNA,
MYC, MIK67) as well as STAT5-regulated (MYC, BCL2)
genes (Fig. 6a)22, and in the induction of apoptosis assayed
by PARP-cleavage fragment p26 (Fig. 6b). In line with
these observations, downregulation of the gene set related
to activation of STAT5 pathway was highlighted by GSEA
(Fig. 6c). Upregulation of SOCS3 and downregulation of
PCNA, MYC, MIK67, and BCL2 genes were also found in
both ex vivo shBRD9-transduced leukemic samples (Fig.
6d and Supplementary Fig. 4a).
To further investigate the involvement of BRD9 in
regulating the STAT5 pathway, we overexpressed GFP-
BRD9 in U937 and K562 cell lines. As expected, lower
SOCS3 and higher pSTAT5 protein levels were observed
in BRD9-enriched cells than in control, indicating the
BRD9-mediated activation of STAT5 pathway supporting
AML tumorigenesis (Fig. 6e and Supplementary Fig. 5b).
Taken together, these results show that BRD9 is a key
regulator for STAT5 activation in leukemia via regulation
of SOCS3 expression.
Discussion
In the present study we identify BRD9 as a key regulator
of AML tumorigenesis and offer new insights into the role
of BRD9 in hematological malignancies. We showed that
the expression of BRD9 is higher in both primary and
leukemic cell lines than in CD34+ cells. By targeting
BRD9, we provided evidence that BRD9 regulates AML
cancer cell proliferation and tumorigenicity, indicating its
proto-oncogenic role in transformed blood cells. In sup-
port of these ﬁndings, we identiﬁed impairment of cell
cycle progression and induction of apoptosis pathways via
caspase8 activation as the most prominent phenotypic
effects upon BRD9 KD. We also analyzed induction of
differentiation following BRD9 depletion, but, in contrast
with a previous study23, we did not observe leukemia cell
differentiation.
We identiﬁed SWI–SNF complex members as the
strongest interactors of BRD9, indicating its involvement
in chromatin remodeling and transcriptional regulation.
Intriguingly, by analyzing BRD9 chromatin-wide binding
sites we found that BRD9 binding mainly occurs at the
enhancer level in a cell type-speciﬁc manner, regulating
cell type-related processes. It is interesting to speculate
that BRD9-related processes might be responsible for cell
identity. Speciﬁcally, BRD9 chromatin binding in AML
mainly regulates immune response-related genes. Con-
versely, at promoter level, BRD9 primarily co-occurs at
the same genomic sites in different cell types, regulating
common cellular processes such as transcription. Our
ﬁndings are in agreement with a recent publication
identifying the SWI/SNF subunit member SMARCB1 as
required to target the SWI/SNF to speciﬁc enhancer
regions and provide new insights into BRD proteins to a
cancer-related SWI/SNF function. However, the role of
BRD9 and its cell-context dependency in other cancers
and diseases still needs to be addressed.
To explore BRD9 upregulation in leukemia, we analyzed
epigenetic marks in BRD9 regulatory regions of AML
patient’s cohort compared with normal progenitors and
differentiated cells; unfortunately, we did not highlight
signiﬁcative differences between them. Thus, BRD9
upregulation in leukemia could be due to a genetic
alteration or overexpression of “positive BRD9 reg-
ulators”. The combination of proteomic experiments in
different leukemic cell lines and BRD9 motifs analysis may
help in addressing these remaining open questions.
Depletion of BRD9 alters the transcription program of
leukemic cells, inducing enrichment of cell death path-
ways and downregulation of genes involved in cell survi-
val. Among the small percentage of overexpressed in cis
BRD9-regulated genes, we identiﬁed SOCS3 as a promi-
nent target responsible for the observed BRD9-depleted
phenotype. Furthermore, we showed for the ﬁrst time that
by negatively regulating SOCS3 expression, BRD9 in turn
inﬂuences activation of the tumor-driver STAT5 pathway,
affecting leukemic cell proliferation and survival. Our
ﬁndings are also supported by a recent report describing
that inhibition of STAT5 is associated with apoptosis
induction via Caspase8 activation24. Accordingly, inhibi-
tion of BRD9 in leukemia reduces STAT5 activation and
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induces apoptosis via Caspase8 and not Caspase9 clea-
vage. The STAT5 pathway and its involvement in cancer
initiation and progression has been extensively studied25.
Although major efforts are being directed toward the
development of inhibitors targeting STAT molecules,
particularly STAT5, candidate compounds have not yet
shown sufﬁcient promise to advance to clinical trials26.
Consequently, inhibiting BRD9 may represent not only a
possible approach to targeting leukemia but also an
alternative strategy to target pSTAT5-driven tumors.
Moreover, as it was shown that healthy cells are able to
survive at low levels of STAT5 activation27, targeting
STAT5 via BRD9 inhibition may also represent a very
promising approach for developing anticancer com-
pounds displaying low toxicity.
Recently, BRD9 inhibitors (BRD9i) such as LP99 and I-
BRD9 were synthetized28,29. These molecules display
selective afﬁnity for BRD9, inhibiting its binding to
chromatin. We treated leukemic cells with LP99, but we
did not observe a signiﬁcant alteration of cell
proliferation.
Although other BRD9i showing a higher afﬁnity to
BRD9 were very recently synthetized and should thus be
tested in future investigations12, an intriguing explanation
for LP99 failure in our settings might be attributed to the
large diversity of protein interaction domains or to a
combination of interaction domains that are able to
anchor the SWI/SNF complex to speciﬁc sets of chro-
matin sites independently of BRD9. This hypothesis is also
supported by recent evidence showing that PFI-3, a
selective SMARCA4/2 BRDi, fails to phenocopy the
observed SMARCA2-depleted phenotype in SMARCA4-
deﬁcient lung cancer cells.
Using BRD9i alone or in combination with other SWI/
SNF and reader inhibitors may nevertheless represent a
potential new approach for future anticancer therapy30,31.
Collectively, our ﬁndings identify BRD9 as a driver
sustaining proliferation and survival of leukemic cells, and
point to its potential as a therapeutic target in leukemia.
Materials and methods
Cell culture
K562, U937, HL-60, KASUMI, NB4, OCI-AML2,
MOLM-14, THP, and KG-1 cells (DMSZ, Germany) were
cultured in RPMI 1640 (Euroclone, Italy) supplemented
with 10% heat-inactivated fetal bovine serum (FBS)
(Sigma-Aldrich, Italy), 2 mM L-glutamine (Euroclone),
and antibiotics (100 U/mL penicillin, 100 μg/mL strepto-
mycin, and 250 ng/mL amphotericin-B). HEK293FT,
U87MG, HeLa, HCT116, and HCT116 p53−/− cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
(Euroclone) supplemented with 10% FBS, 100 U/mL
penicillin/streptomycin (Euroclone), and 6mM
(HEK293FT) or 2 mM glutamine (Euroclone). Transgenic
HeLa cells overexpressing GFP-BRD9 were cultured in
DMEM supplemented with heat-inactivating FBS, 2 mM
L-glutamine, 1% penicillin/streptomycin, 50 μg/mL
hygromycin (Thermo Fisher Scientiﬁc, Italy), and 2 μg/mL
blasticidin S (Sigma-Aldrich).
Primary cell culture
Leukemic blasts cells were recovered from the periph-
eral blood or bone marrow of leukemic patients and
puriﬁed by Ficoll density gradient separation (Sigma-
Aldrich). Cells were cultured in RPMI 1640 (Euroclone)
supplemented with 20% heat-inactivated FBS (Sigma-
Aldrich), 1% glutamine (Euroclone), 1% penicillin/strep-
tomycin (Euroclone), and 0.1% gentamycin (Euroclone).
All experiments were approved by the University of
Campania “L. Vanvitelli” ethical committee. CD34+ cells
were purchase from STEMCELL TECHNOLOGIES (US)
Catalog # 70002.
GFP pull-down assay and WB analysis
GFP pull-down assay was performed as previously
described32.
For WB analysis, cells were lysed in RIPA buffer (1%
Triton X-100, 0.1% SDS, 150 mM NaCl, 1 mM EDTA pH
8, 10 mM Tris-HCl pH 8, and 1% protease inhibitor
cocktail (Roche, Italy) centrifuged for 15 min at 4 °C and
heated for 5 min at 95 °C; 25 µg of protein extract was
subjected to SDS-polyacrylamide gel electrophoresis,
blotted on PVC membrane (Bio-Rad, USA) and incubated
overnight with appropriate antibodies. Relative protein
expression was detected by ECL Chemiluminescence
method (Bio-Rad). Bands intensity were quantiﬁed by
Image J analysis.
qPCR and primers
RNA extraction was performed using TRIzol (Thermo
Fisher Scientiﬁc) according to supplier’s instructions. Five
hundred nanograms of RNA was reverse transcribed
using SuperScript VILO DNA Synthesis Kit (Thermo
Fisher Scientiﬁc), as described by the manufacturer’s
protocol. Quantitative real-time PCR was carried out with
a Bio-Rad iCycler iQ Real-Time PCR Detection System
using iQ SYBR Green Supermix (Bio-Rad). Analysis was
performed by ΔΔCt method.
Primers are listed in Table 2.
Colony-formation assay
Colony-forming capability of leukemic U937 cells was
assayed by MethoCult H4535 enriched without ery-
thropoietin EPO (Stemcell Technologies, Canada),
according to the manufacturer’s instructions. Cells
(1 × 104) were cultured in triplicate and number of colo-
nies was scored after 2 weeks. Colonies quantiﬁcation was
performed as previously described33.
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AnnexinV–APC assay
AnnexinV–Allophycocyanin (APC) staining assay was
purchased from BD Biosciences (USA) and used accord-
ing to the manufacturer’s instruction.
Antibodies, plasmids, and chemicals
Primary antibodies used for WB were as follows: anti-
BRD9 (Bethyl Laboratories, A303-781A), anti-Cyclin E1
(Abcam, ab3927), anti-ERK1/2 (SantaCruz Biotechnology,
SC-94), anti-GFP (Abcam, ab290), anti-p21 (Cell Signal-
ing Technology, #2947), anti-PARP (Abcam, ab32138),
anti-STAT5 (Abcam, ab209544), anti-pSTAT5 (Abcam,
ab32364), anti-SOCS3 (Abcam, ab16030), anti-Actin
(Abcam, ab3286), and anti-SMARCA4 (Abcam, ab4081).
Primary antibody used for ChIP was anti-BRD9 (Active
Motifs, 61538). Antibodies were used according to the
manufacturer’s instructions.
Caspase8 Z-IETD and Caspase9 inhibitor Z-LEHD were
purchased from R&D System and were used at 100 μM.
Lentiviral shRNAs targeting BRD9 (TRC0000131081,
TRC0000127634) and scrambled control (TRC000035)
plasmids were from Sigma MISSION human shRNA
library (Sigma-Aldrich); pcDNA5_FRT plasmid was
kindly provided by Professor M. Vermeulen;
pcDNA5_FRT-BRD9 was generated by cloning the PCR-
ampliﬁed coding sequence region of BRD9 in KpnI-XhoI
digested pcDNA5_FRT vector; psPAX2 and pMD2.G
were kindly provided by Professor A. Baldini.
Lentiviral production and cell transduction
HEK293FT cells were transfected using Lipofectamine
2000 reagent (Thermo Fisher Scientiﬁc) according to the
manufacturer’s instructions.
For lentiviral production, HEK293FT cells were tran-
siently co-transfected with lentiviral plasmid and lentiviral
packaging plasmids psPAX2 and pMD2.G in a ratio of
3:2:3. Collected cell supernatant was centrifuged and the
lentiviral particle pellet was resuspended in
200 µl DMEM.
For cell transduction, 50 µl DMEM containing lentiviral
vectors was added to 1 × 106 cells. Cells were selected in
puromycin at a ﬁnal concentration of 1 µg/ml for 7 days.
Cell cycle and PI analysis
Cells (2.0 × 105) were collected, washed with phosphate-
buffered saline (PBS) once, and resuspended in hypotonic
buffer (0.1% NP-40, 0.1% sodium citrate, 50 µg/µL PI,
RNAse A). Cells were then incubated in the dark for at
least 30 min and measured by FACS Calibur ﬂow cyt-
ometer (Becton Dickinson). For PI analysis, cells were
collected, washed with PBS twice, resuspended in PI
buffer (0.2 µg/µL PI, PBS 1%) and measured on FACS
Calibur ﬂow cytometer. Flow cytometric data were
analyzed using ModFit (Verity), FlowJo 9.3, and Cell
Quest (Becton Dickinson) technologies.
Generation of inducible HeLa cell line overexpressing
BRD9
HeLa-FRT cell line constitutively expressing TetR was
provided by Professor M. Vermeulen. Cells were tran-
siently transfected by Lipofectamine 2000, according to
the supplier’s instructions, with pcDNA5_FRT-BRD9 and
pOG44 plasmids. GFP-BRD9 HeLa cells were then
selected with 100 μg/mL hygromycin B (Thermo Fisher
Scientiﬁc) and 3 μg/mL blasticidin S (Sigma-Aldrich). To
induce GFP-BRD9 expression, cells were treated over-
night with 1 μg/mL doxycycline (Sigma-Aldrich).
Nucleofection of leukemic cells
Nucleofection of U937 and K562 cells was performed
using Amaxa Nucleofector Kit C and Kit V (Lonza),
respectively, according to the manufacturer’s protocol.
Nuclear extraction and label-free GFP pulldown for MS
analysis
Nuclear extraction was performed as previously repor-
ted34. Brieﬂy, HeLa cells expressing GFP-BRD9 (GFP-
BRD9 HeLa) and wild-type HeLa cells were colleced and
homogenized using a tight pestle in the presence of 0.15%
NP-40 (Roche) and complete protease inhibitors (Roche).
Samples were then incubated in hypotonic buffer. The
nuclei were pelleted by centrifugation and incubated with
lysis buffer (420 mM NaCl, 0.1% NP-40, and complete
protease inhibitors) for 1 h to extract nuclear proteins.
The nuclear extract was obtained by a ﬁnal centrifugation
step at 13,000 r.p.m. for 30 min at 4 °C. The GFP-BRD9
HeLa and wild-type HeLa nuclear extracts were subjected
to GFP pulldown using GFP-trap beads (Chromotek). For
each pulldown, 1 mg of nuclear extract was incubated
with 15 μL beads in incubation buffer (300 mM NaCl,
0.15% NP-40, 0.5 mM dithiothreitol, 20 mM
HEPES–KOH pH 7.9) containing ethidium bromide at a
ﬁnal concentration of 50 mg/mL. Ethidium bromide was
added to the reaction to prevent indirect, DNA-mediated
interactions. Beads were then washed twice with incuba-
tion buffer containing 0.5% NP-40, twice with PBS con-
taining 0.5% NP-40, and ﬁnally twice with PBS only.
Sample preparation and MS analysis
Sample preparation and MS analysis were performed as
previously described35. For MS data analysis, raw data
were analyzed by MaxQuant software (version 1.5.1.0)
using standard settings and the additional options match
between runs, LFQ, and iBAQ. Volcano plots were gen-
erated as previously described32 using Perseus version
1.4.0.8 and in-house R scripts.
Del Gaudio et al. Cell Death and Disease          (2019) 10:338 Page 11 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
RNA sequencing
RNA-seq and RNA-seq analysis were performed as
previously reported36. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository with the data set
identiﬁer PXD013245.
Chromatin preparation
Chromatin preparation was essentially performed as
previously described37 with some modiﬁcations. Brieﬂy,
U937 and HeLa cells were protein crosslinked using
2mM Disuccinimidyl Glutarate (DSG) for 45min at room
temperature (RT). Cells were then washed twice with PBS
and DNA crosslinking was performed with 1% for-
maldehyde for 15min (U937) or 10min (HeLa) at RT
with gentle shaking. Crosslinking reaction was quenched
using 1.25M glycine. Cells were then washed with PBS
twice and collected in Buffer B (20 mM HEPES, 0.25%
Triton X-100, 10 mM EDTA, and 0.5 mM EGTA). Cells
were pelleted by centrifuge at 2000 r.p.m. for 5 min at 4 °C
and resuspended in Buffer C (150 mM NaCl, 50 mM
HEPES, 1 mM EDTA, and 0.5 mM EGTA). After that,
cells were pelleted and resuspended in 1× incubation
buffer (0.15% SDS, 1% Triton X-100, 150mM NaCl,
1 mM EDTA, 0.5 mM EGTA, and 20mM HEPES) at 15
million cells/mL. Cells were sheared in a Bioruptor Pico
sonicator (Diagenode) at 4 °C using 6 (U937) or 7 cycles
(HeLa) of 30 s ON, 30 s OFF. Sonicated material was
centrifuged at 13,000 r.p.m. for 15 min at 4 °C, then stored
at −80 °C.
Chromatin immunoprecipitation
Cells (10 × 106) were used as input for library prepara-
tion and 5 × 106 cells were used as input for ChIP-qPCR
experiments. Chromatin was pre-cleaned by incubating
with Protein A/G Dynabeads (Invitrogen) for 90 min at
4 °C in 1× incubation buffer (0.15% SDS, 1% Triton X-100,
150mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and 20mM
HEPES) supplemented with protease inhibitors and 0.1%
bovine serum albumin (BSA). Chromatin was then incu-
bated with 5 µg of antibody overnight at 4 °C in 1×
incubation buffer supplemented with protease inhibitors
and 0.1% BSA. Protein A/G Dynabeads were added the
day after followed by a 90 min incubation. The beads were
washed twice with Wash Buffer 1 (0.1% SDS, 0.1% sodium
deoxycholate, 1% Triton, 150mM NaCl, 1 mM EDTA,
0.5 mM EGTA, and 20mM HEPES), once with Wash
Buffer 2 (Wash Buffer 1 with 500mM NaCl), once with
Wash Buffer 3 (250 mM LiCl, 0.5% sodium deoxycholate,
0.5% NP-50, 1 mM EDTA, 0.5 mM EGTA, and 20mM
HEPES), and twice with Wash Buffer 4 (1 mM EDTA,
0.5 mM EGTA, and 20mM HEPES). After washing, beads
were rotated for 30 min at RT in Elution Buffer (1% SDS,
0.1M NaHCO3). The supernatant was decross-linked
with 200mM NaCl and 100 μg/mL Proteinase K over-
night at 65 °C. Decross-linked DNA was puriﬁed by
MinElute PCR Puriﬁcation columns (Qiagen). DNA
amount was quantiﬁed using Qubit ﬂuorometric quanti-
tation (Thermo Fisher Scientiﬁc).
ChIP-seq and RNA-seq processing
ChIP-seq reads were aligned using BWA-ALN mapper
against the hg19 reference human genome. The reads
marked as PCR duplicates and with mapping quality score
<15 were removed from further analysis. Peak calling was
performed by MASC2 using a Q-value cutoff of 0.01.
Peaks were annotated using Homer software. ChIP-seq
and RNA-seq data have been deposited in NCBI's Gene
Expression Omnibus database and are accessible through
GEO Series accession number: GSE129437.
RNA-seq reads were aligned using Bowtie mapper
against the GRCh37.72 reference human transcriptome.
The reads with mapping quality score <15 were removed
from further analysis. Mapped transcripts were quantiﬁed
using MMSEQ pipeline.
Downstream analyses were performed using R built-in
packages, gplots, ggplot2, and ﬂuff. GSEA analysis was
performed against MSig cancer hallmark database.
Public ChIP-seq datasets used for this study are listed in
the table below (Table 1).
Primers
Primers used for this study are listed in the table below
(Table 2).
Statistical analysis
Statistical analysis was performed by two-tailed
unpaired t-test. P < 0.05 was considered signiﬁcant. All
experiments were performed in three biological and three
technical replicates (unless differently speciﬁed in
the text).
Table 1 Public ChIP-seq datasets
ChIP Cell line GEO accession number
H3K4me3 U937 GSM1486000, GSM1486001
HeLa, HeLa-Kyoto GSM501713, GSM566169
H3K9K14ac U937 GSM585614
HeLa-Kyoto GSM566174
POLD2A U937 GSM726988
HeLa GSM1088665
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